Search research articles
Contact Us
Filters
Showing results (91-100 of 189) with videos related to
Page
of 19
Sort By:
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
October 1, 1994
Do bacteriuria and candiduria have predictive value in the diagnosis of postlaparotomy peritonitis?
T Bensousan, J M Dray, F Vincent, et al.
European Journal of Cardio-Thoracic Surgery : Official Journal of the European Association for Cardio-Thoracic Surgery
|
October 23, 1997
Should the number of pulmonary metastases influence the surgical decision?
P Girard, L Spaggiari, P Baldeyrou, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 13, 1997
Response rate accuracy in oncology trials: reasons for interobserver variability. Groupe Français d'Immunothérapie of the Fédération Nationale des Centres de Lutte Contre le Cancer
P Thiesse, L Ollivier, D Di Stefano-Louineau, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 19, 2000
Treatment of patients with metastatic renal carcinoma with a combination of subcutaneous interleukin-2 and interferon alfa with or without fluorouracil. Groupe Français d'Immunothérapie, Fédération Nationale des Centres de Lutte Contre le Cancer
S Négrier, A Caty, T Lesimple, et al.
Oncogene
|
January 25, 2011
Mutations of the von Hippel-Lindau gene confer increased susceptibility to natural killer cells of clear-cell renal cell carcinoma
A Perier, G Fregni, S Wittnebel, et al.
British Journal of Cancer
|
April 13, 2013
Patient-reported outcomes for axitinib vs sorafenib in metastatic renal cell carcinoma: phase III (AXIS) trial
D Cella, B Escudier, B Rini, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 22, 2015
Reply to the letter to the editor 'Ablative therapies for lung metastases: a need to acknowledge the efficacy and toxicity of stereotactic ablative body radiotherapy' by Siva et al
T de Baère, A Aupérin, F Deschamps, et al.
European Radiology
|
May 9, 2015
mTOR-inhibitor treatment of metastatic renal cell carcinoma: contribution of Choi and modified Choi criteria assessed in 2D or 3D to evaluate tumor response
M Lamuraglia, S Raslan, R Elaidi, et al.
The Journal of Urology
|
May 19, 2009
Sequential sorafenib and sunitinib for renal cell carcinoma
M P Sablin, S Negrier, A Ravaud, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 22, 2019
Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†
B Escudier, C Porta, M Schmidinger, et al.
Page
of 19
Search research articles
Search
Showing results (91-100 of 189) with videos related to
Sort By:
Page
of 19
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
October 1, 1994
Do bacteriuria and candiduria have predictive value in the diagnosis of postlaparotomy peritonitis?
T Bensousan, J M Dray, F Vincent, et al.
European Journal of Cardio-Thoracic Surgery : Official Journal of the European Association for Cardio-Thoracic Surgery
|
October 23, 1997
Should the number of pulmonary metastases influence the surgical decision?
P Girard, L Spaggiari, P Baldeyrou, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 13, 1997
Response rate accuracy in oncology trials: reasons for interobserver variability. Groupe Français d'Immunothérapie of the Fédération Nationale des Centres de Lutte Contre le Cancer
P Thiesse, L Ollivier, D Di Stefano-Louineau, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 19, 2000
Treatment of patients with metastatic renal carcinoma with a combination of subcutaneous interleukin-2 and interferon alfa with or without fluorouracil. Groupe Français d'Immunothérapie, Fédération Nationale des Centres de Lutte Contre le Cancer
S Négrier, A Caty, T Lesimple, et al.
Oncogene
|
January 25, 2011
Mutations of the von Hippel-Lindau gene confer increased susceptibility to natural killer cells of clear-cell renal cell carcinoma
A Perier, G Fregni, S Wittnebel, et al.
British Journal of Cancer
|
April 13, 2013
Patient-reported outcomes for axitinib vs sorafenib in metastatic renal cell carcinoma: phase III (AXIS) trial
D Cella, B Escudier, B Rini, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 22, 2015
Reply to the letter to the editor 'Ablative therapies for lung metastases: a need to acknowledge the efficacy and toxicity of stereotactic ablative body radiotherapy' by Siva et al
T de Baère, A Aupérin, F Deschamps, et al.
European Radiology
|
May 9, 2015
mTOR-inhibitor treatment of metastatic renal cell carcinoma: contribution of Choi and modified Choi criteria assessed in 2D or 3D to evaluate tumor response
M Lamuraglia, S Raslan, R Elaidi, et al.
The Journal of Urology
|
May 19, 2009
Sequential sorafenib and sunitinib for renal cell carcinoma
M P Sablin, S Negrier, A Ravaud, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 22, 2019
Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†
B Escudier, C Porta, M Schmidinger, et al.
Page
of 19